Published November 2021 | Version v1
Journal article

Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study)

Contributors

Others:

Description

Advanced non-squamous non-small cell lung cancer (NsqNSCLC) progressing at the induction of a first-line of platin-based chemotherapy is a subgroup of patients with poor prognosis and few second-line treatment options.

Abstract

International audience

Additional details

Identifiers

URL
https://inria.hal.science/hal-03524385
URN
urn:oai:HAL:hal-03524385v1

Origin repository

Origin repository
UNICA